MedTrace Logo

Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata

NCT03137381 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 149

Last updated 2022-07-19

Study results available
· View outcomes & findings →

Summary

This study will evaluate the safety and efficacy of CTP-543 on hair loss in adults with chronic, moderate to severe alopecia areata.

Conditions

Interventions

DRUG

CTP-543

Administered as tablets.

DRUG

CTP-543 matching placebo

Administered as tablets.

Sponsors & Collaborators

  • Concert Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Colleen E. Hamilton · Concert Pharmaceuticals, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-09
Primary Completion
2019-07-08
Completion
2019-07-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03137381 on ClinicalTrials.gov